SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Avenue Therapeutics, Inc. (ATXI) , forward earnings yield 212.77%.
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+2252.9%).
- Forward P/E 0.5
- Analyst consensus target $12.00 (+2252.9% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 53/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ATXI
Valuation Multiples
P/E (TTM)0.0
Forward P/E0.5
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio1.14
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.93
Forward EPS (Est.)$1.09
Book Value / Share$0.00
Revenue / Share$0.45
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield212.77%
Dividend Yield0.00%
Analyst Target$12.00 (+2252.9%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-5.39 |
$0.00 |
$-3.18M |
- |
| 2017 |
$-27.71 |
$0.00 |
$-12.26M |
- |
| 2018 |
$-31.17 |
$0.00 |
$-21.55M |
- |
| 2019 |
$-24.38 |
$0.00 |
$-25.91M |
- |
| 2020 |
$-4.65 |
$0.00 |
$-5.15M |
- |
| 2021 |
$-3.29 |
$0.00 |
$-3.73M |
- |
| 2022 |
$-1.63 |
$0.00 |
$-3.55M |
- |
| 2023 |
$-73.48 |
$0.00 |
$-10.38M |
- |
| 2024 |
$-0.90 |
$0.00 |
$-11.65M |
- |
| 2025 |
$-0.93 |
$1.4M |
$-2.91M |
-207.2% |
